Production and Market Strategy - The company has halted the production of Vitamin B12 due to market reasons [2] - In 2024, the production of biological enzyme preparations reached 41,533 tons, with sales of 42,383 tons, indicating a near-saturation capacity utilization [2] - The company is focusing on expanding its global market presence, having registered products in over 30 countries and established long-term partnerships with over 2,300 clients [2] Research and Development - The company has made progress in developing new products, including plant extracts and fermentation products, while optimizing extraction processes for various plants [2] - New product certifications have been obtained for feed and feed additives, enhancing the company's product portfolio [2] Financial Performance and Shareholder Engagement - As of September 10, 2025, the number of shareholders is 20,222 [4] - The management is committed to improving company performance and achieving the goals set in the equity incentive plan over the next three years [5] - The company is actively engaging in value management through cash dividends, share buybacks, and equity incentives [6] Market Position and Challenges - The company is addressing the challenge of its stock price being close to net asset value, which is uncommon for growth stocks [5] - The management emphasizes the importance of maintaining a strong domestic market position while pursuing international expansion [5]

Group 1: Financial Performance and Goals - The company aims to achieve an annual profit target of 100 million yuan, despite a modest performance in the first half of the year [2][5] - Management expresses confidence in meeting performance assessment goals set by the employee stock ownership plan and equity incentives [2][5] Group 2: Product Development and Partnerships - The company has developed self-researched liquid cooling solutions, including micro-channel layered water cooling heads, to meet high-power heat dissipation needs [4][7] - Collaboration with North American cloud service providers is ongoing, with G customer orders experiencing a year-on-year doubling and N customer orders expected to grow rapidly throughout the year [3][7] Group 3: Market Position and Strategy - The company is transitioning from being an equipment supplier to a product supplier, aiming to better serve customer needs [3][4] - The subsidiary Bojie Chip has developed various cutting machines, achieving market breakthrough with competitive pricing at approximately 50-67% of foreign counterparts [5][6] Group 4: Future Outlook and Investor Relations - The company is committed to enhancing information disclosure and value communication to better present its value to investors [5][7] - The company is currently not involved in solid-state battery production but is monitoring industry trends [5][6]

Production Capacity and Market Position - The company is currently constructing a pilot production line for high-performance samarium-cobalt magnets, expected to complete by the end of September 2025, with initial production capacity planned for small batches [1][5]. - The global competitors in this field include companies like Hitachi Metals and Sumitomo, with the total global production capacity not specified [1][2]. - The maximum magnetic energy product of the samarium-cobalt products has reached over 12 MGOe [3][6]. MIM Products and Technological Development - The MIM (Metal Injection Molding) product line is still in its early stages, focusing on technology optimization and market expansion [2][3]. - The company has developed a series of high-density and high-precision components for various applications, including automotive and consumer electronics [9][10]. - The MIM products are expected to enhance the company's competitive edge as they continue to innovate and expand their product matrix [2][9]. Acquisition and Strategic Growth - The acquisition of Guangzhou Jinnan Magnetic Materials Co., Ltd. is in progress, with due diligence and auditing being conducted [2][5]. - Successful completion of the acquisition is anticipated to enhance the company's global competitive advantage through synergistic effects in technology and market reach [10][11]. - The company aims to optimize its supply chain and reduce costs through integrated procurement strategies post-acquisition [10][11]. Financial Performance and Market Trends - The revenue from radiation protection materials has doubled year-on-year, primarily driven by demand in the medical and security inspection sectors [8][9]. - The company is actively expanding its market presence in non-U.S. regions, particularly in Europe and Southeast Asia, despite challenges posed by international trade policies [8][9]. - The company is focused on enhancing its profitability and market competitiveness through continuous innovation and strategic market expansion [4][10].

证券代码：002212 证券简称：天融信 天融信科技集团股份有限公司 投资者关系活动记录表 编号：2025-004 投资者关系活 动类别 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 √其他（2025 年广东辖区投资者网上集体接待日活动） 参与单位名称 及人员姓名 通过"全景路演"网站（https://rs.p5w.net）参与 2025 年广东辖区投 资者网上集体接待日活动的投资者。 因本次投资者网上集体接待日活动采取网络远程的方式举行，参会 者无法签署调研承诺函。但在交流活动中，我公司严格遵守相关规定，保 证信息披露真实、准确、及时、公平，没有发生未公开重大信息泄露等情 况。 时间 2025 年 09 月 19 日 15:30-17:00 地点 "全景路演"网站（https://rs.p5w.net） 形式 网络远程方式 上市公司 接待人员姓名 李雪莹：董事长、总经理 孔继阳：董事、副总经理、财务负责人 吴亚飚：董事、副总经理 彭韶敏：副总经理、董事会秘书 1 1、随着 AI 发展，云业务重要性越来越高，公司云业务发展怎样？ 和华为合作进展怎样？ 答：公司自 ...

Group 1: Company Collaboration and Product Development - The company is actively pursuing deep ecological cooperation with upstream and downstream manufacturers in the industry, including potential collaborations with Alibaba, Huawei, and Tencent [2][3]. - The company is focusing on the development of new computing power products, with plans for new product launches from this year to the first half of next year [2][3]. - The JM11 series graphics processing chips are currently in the promotion application stage, aimed at building a domestic GPU application ecosystem [3][4]. Group 2: Financial Performance and Market Strategy - The company is addressing fluctuations in its operating performance due to industry demand, project delays, increased R&D investment, and intense market competition [5][6]. - The company is committed to enhancing operational efficiency and expanding its business scope to adapt to the competitive market environment [5][6]. - The company is expected to disclose its third-quarter performance report for 2025, which will provide insights into its financial recovery [6][7]. Group 3: Investor Relations and Communication - The company encourages investors to refer to official announcements for updates on external collaborations and product development plans [2][3]. - The company is actively engaging with investors through online platforms, addressing questions regarding product sales, project progress, and market strategies [2][3][4]. - The company acknowledges the importance of maintaining investor confidence and is exploring reasonable ways to boost stock prices while focusing on operational growth [4][5].

Group 1: Company Overview and Sales Model - The company specializes in home hardware products, including sliding rails, hinges, and kitchen and bathroom accessories, serving industries such as custom furniture and appliances [2][3] - The sales model combines direct sales and agency sales, focusing on large clients while expanding the agency network to cover various markets [3][6] - As of the first half of 2025, domestic and international sales each accounted for 50%, with channel sales making up approximately 30% [6] Group 2: Core Competencies - Key competitive advantages include R&D and technological innovation, particularly in smart and automated products [4] - Lean manufacturing and cost control are emphasized to maintain product consistency and reliability while optimizing costs [4] - A robust channel network and customer service capabilities are crucial for market penetration and customer retention [4] Group 3: Market Differentiation - Domestic brands offer high cost-performance ratios and rapid product iteration compared to foreign brands, which are often associated with higher price points [5][6] - Domestic companies have extensive coverage from urban to rural areas, establishing strong ties with small furniture manufacturers and renovation companies [5] - Brand awareness is rapidly increasing for leading domestic firms through digital marketing strategies, while foreign brands maintain a reputation for high-end reliability [5][6] Group 4: Future Market Drivers - The demand for renovation and partial upgrades in existing homes is a significant growth driver as the real estate market matures [7] - Consumer preferences are shifting towards higher quality and functionality, leading to increased demand for premium hardware products [7] - The trend of full-house customization is growing, requiring higher standards for hardware components [7] - Upgrades in manufacturing and supply chain integration are enhancing efficiency and market share for leading companies [7]

| | 特定对象调研 | 分析师会议 | | --- | --- | --- | | 投资者关系活动类 | 媒体采访 | □业绩说明会 | | 别 | 新闻发布会 | □路演活动 | | | 现场参观 | | | | | 其他（请文字说明其他活动内容） | | | 民生证券 尹会伟 | | | | 民生证券 孔厚融 | | | | 开源证券 李苗钰 | | | | 广发证券 吴坤齐 | | | | 前海人寿保险 | 程正隆 | | | 陕西海拓实业发展有限公司 | 王谨 | | | 众安在线财产保险 | 徐赛 | | | 嘉实基金 王维 | | | 参与单位名称及人 | 国联民生 樊景扬 | | | 员姓名 | 中信证券 陈卓 | | | | 中信证券 梁爽 | | | | 中信证券 韩晨 | | | | 西安普潓年华健康体检有限公司 | 刘军龙 | | | 西安普潓年华健康体检有限公司 | 蒋先运 | | | 陕西富田化肥有限公司 | 商阳 | | | 国盛证券 乾亮 | | | | 国盛证券 彭元立 | | | 时 间 | | 2025年9月16日、2025年9月17日、2025年9月19日 ...

Group 1: Company Overview - Boji Pharmaceutical Technology Co., Ltd. primarily operates as a CRO service provider, offering outsourced pharmaceutical research and development services, focusing on innovative drugs across various therapeutic areas [2][4]. - The company has multiple self-developed projects at different research stages, although none have reached the market sales stage yet [4]. Group 2: Clinical Trials and Product Development - The project involving "Semaglutide Injection" is currently in the clinical trial follow-up phase, with the timeline for completion and market application dependent on project progress and client drug approval schedules [3][4]. - Current research projects include traditional Chinese medicine innovative drugs for chronic heart failure and small molecule new drugs for conditions like hyperuricemia and reversible cataracts [4]. Group 3: Financial Performance and Market Position - The company emphasizes improving operational quality as a core aspect of market value management, acknowledging the disparity between its stock price and the performance of innovative drug indices [5]. - For the first half of 2025, the company's R&D expenditure was approximately 2,320,000 yuan, accounting for about 6% of its revenue [6]. Group 4: Investment and Asset Management - The company manages idle funds by investing in safe, liquid, and low-risk financial products, avoiding high-risk investments such as stock trading or derivatives [6].

广东德联集团股份有限公司投资者关系活动记录表 | 投资者关系活动 | 特定对象调研 □ 分析师会议 | □ | | --- | --- | --- | | 类别 | 媒体采访 □ 业绩说明会 | □ | | | 新闻发布会 路演活动 □ | □ | | | 现场参观 | □ | | | 其他 （广东辖区 年投资者网上集体接待日活动） 2025 | √ | | 参与单位名称及 | 线上参与广东辖区 2025 年投资者网上集体接待日活动的投资者 | | | 人员姓名 | | | | 时间 | 年 9 月 19 日 （周五） 下午 15:30~17:00 | 2025 | | 地点 | 全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 上市公司接待人 | 1、董事长、总经理 徐团华 | | | 员姓名 | 2、董事、副总经理 徐庆芳 | | | | 3、董事会秘书 陶张 | | | | 4、财务总监 谭照强 投资者提出的问题及公司回复情况 | | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | | 1、贵公司液冷产品在手订单有多少？ | | | | 尊敬的投资者 ...

| | 答：您好，2025 年上半年，公司营收 亿元，同比增长 2.70 | | --- | --- | | | 万元，同比下降 15.82%；归母净利润 1471.07 9.35%。收入增长 | | | 得益于市场开拓与产品结构优化。利润下降主要是受公司增资扩 | | | 产项目部分在建工程转固以及转固后相关借款利息费用化影响， | | | 导致期间费用增加。此外，2024 年公司计提减值主要是计提存 | | | 货跌价准备所致，不具有持续性。感谢您的关注。 | | 附件清单（如有） | | | 日期 | 2025-09-19 | 东莞金太阳研磨股份有限公司投资者关系活动记录表 | 投资者关系活动 □ | 特定对象调研 □ 分析师会议 | | --- | --- | | 类别 □ | 媒体采访 □ 业绩说明会 | | □ | 新闻发布会 路演活动 □ | | □ | 现场参观 | | ☑ | 其他 （2025 年广东上市公司投资者关系管理月活动投资者 | | | 集体接待日） | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 2025 年 9 月 19 日 (周五) 下午 ...